Skip to main content

Advertisement

SpringerLink
Log in

sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia

  • FRONTIERS IN AUTOIMMUNITY
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Ferritin has a key role in Adult-onset Still’s disease (AOSD). Its production seems related to macrophage activation of which sCD163 is a major serum marker. Thus, we aimed at evaluating the role of sCD163 in AOSD and its relationship with ferritin. Furthermore, we determined the expression of CD163 and ferritin in a lymph-node from an AOSD patient. sCD163 and serum ferritin were measured in 34 patients with AOSD (21 active, 13 non-active), 18 sepsis and 22 healthy controls (HC). Immunohistology was performed on a lymph-node from an AOSD patient in order to detect CD163 and ferritin. A tonsil from an HC was used as control. Mean sCD163 (8.6 ± 5.4 mg/L) was higher in active AOSD than “non-active” patients (4.6 ± 2.7 mg/L, p = 0.02). The mean sCD163 in AOSD (6.9 ± 4.9 mg/L) and sepsis (7.1 ± 5.6 mg/L) were higher than in HC (2.56 ± 1.17 mg/L, p < 0.001), but no difference between AOSD and sepsis was detected. sCD163 positively correlated with ferritin (p = 0.0045; r = 0.4755) only in AOSD. Serum ferritin (mean 3,640.1 ± 6,896.9 µg/L) was higher in active AOSD than in sepsis (1,720.2 ± 3,882.1 µg/L, p < 0.007). CD163 was equally distributed in the B and T areas of both lymph-node and tonsil. Differently from the tonsil, ferritin was expressed only in the lymph-node B area. sCD163 is a marker of disease activity in AOSD. The correlation with ferritin may lead to hypothesize a macrophage activation related to hyperferritinemia. Ferritin was found expressed only in the B area of the AOSD lymph-node, suggesting a role for this molecule as an antigen in the disease pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6:457–63.

    Article  CAS  PubMed  Google Scholar 

  2. Priori R, Colafrancesco S, Picarelli G, Di Franco M, Valesini G. Adult-onset Still’s disease: not always so good. Clin Exp Rheumatol. 2012;30:142.

    CAS  PubMed  Google Scholar 

  3. Agmon-Levin N, Rosário C, Katz BS, Zandman-Goddard G, Meroni P, Cervera R, Stojanovich L, Blank M, Pierangeli S, Praprotnik S, Meis Ed, Seguro LP, Ruffatti A, Pengo V, Tincani A, Doria A, Shoenfeld Y. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus. 2013;22:1327–35.

    Article  CAS  PubMed  Google Scholar 

  4. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophicantiphospholipid syndrome. BMC Med. 2013;22(11):185.

    Article  Google Scholar 

  5. Kontzias A, Efthimiou P. Adult-onset Still’s disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs. 2008;68:319–37.

    Article  CAS  PubMed  Google Scholar 

  6. Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaiani G, Palazzo D, Valesini G. Interleukin 18: a biomarker for differential diagnosis between adult-onset Still’s disease and sepsis. J Rheumatol. 2014;41:1118–23.

    Article  CAS  PubMed  Google Scholar 

  7. Colafrancesco S, Priori R, Alessandri C, Perricone C, Pendolino M, Picarelli G, Valesini G. IL-18 serum level in adult onset Still’s disease: a marker of disease activity. Int J Inflam. 2012;2012:156890. doi:10.1155/2012/156890.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset still’s disease. J Rheumatol. 2001;28:322–9.

    CAS  PubMed  Google Scholar 

  9. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult still’s disease. J Rheumatol. 1992;19:424–30.

    CAS  PubMed  Google Scholar 

  10. Lian F, Wang Y, Yang X, Xu H, Liang L. Clinical features and hyperferritinemia diagnostic cutoff points for AOSD based on ROC curve: a Chinese experience. Rheumatol Int. 2012;32:189–92.

    Article  CAS  PubMed  Google Scholar 

  11. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010;116:1574–84.

    Article  CAS  PubMed  Google Scholar 

  12. Cairo G, Recalcati S, Mantovani A, Locati M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32:241–7.

    Article  CAS  PubMed  Google Scholar 

  13. Møller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012;72:1–13.

    Article  PubMed  Google Scholar 

  14. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset-Still’s disease and sepsis. 2010;37:2369–76.

    CAS  PubMed  Google Scholar 

  15. American Collage of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure, guide lines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.

    Article  Google Scholar 

  16. Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical significance of soluble hemoglobin scavenger receptor CD163 (sCD163) in sepsis, a prospective study. PLoS One. 2012;7:e38400.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–71.

    Article  CAS  PubMed  Google Scholar 

  18. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, Moller HJ, Moestrup SK, Schaffner A. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6–10.

    Article  CAS  PubMed  Google Scholar 

  19. Mehta B, Efthimiou P. Ferritin in adult-onset still’s disease: just a useful innocent bystander? Int J Inflam. 2012;2012:298405. doi:10.1155/2012/298405.

    PubMed Central  PubMed  Google Scholar 

  20. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99:3505–16.

    Article  CAS  PubMed  Google Scholar 

  21. Torti SV, Kwak EL, Miller SC, et al. The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem. 1988;263:12638–44.

    CAS  PubMed  Google Scholar 

  22. Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun. 2008;30:84–9.

    Article  CAS  PubMed  Google Scholar 

  23. Chen TT, Li L, Chung DH, Allen CD, Torti SV, Torti FM, Cyster JG, Chen CY, Brodsky FM, Niemi EC, Nakamura MC, Seaman WE. Daws MR.TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med. 2005;202:955–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Ghosh S, Hevi S, Chuck SL. Regulated secretion of glycosylated human ferritin from hepatocytes. Blood. 2004;103:2369–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy

    S. Colafrancesco, R. Priori, C. Alessandri, E. Astorri, C. Perricone & G. Valesini

  2. Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Tel-Hashomer, Israel

    M. Blank, N. Agmon-Levin & Y. Shoenfeld

Authors
  1. S. Colafrancesco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Priori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Alessandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Astorri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Perricone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Blank
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Agmon-Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Valesini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Priori.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colafrancesco, S., Priori, R., Alessandri, C. et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res 60, 177–183 (2014). https://doi.org/10.1007/s12026-014-8563-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-014-8563-7

Keywords

Search

Navigation